Sunday, March 16, 2025 | 03:34 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Biocon-Mylan launch insulin Glargine at lowest price in US market

The commercialisation in the US of the drug, which already has approval in 45 countries, gives a boost to Biocon's ambitious target of $1 billion in sales through its biologics division by FY22

Biocon likely to channelise investments towards non-insulin biologics
Premium

Biocon has been expanding affordable access to biosimilar insulins to patients in Japan, Australia, Europe, India and key emerging markets

Samreen Ahmad Bengaluru
Biotechnology major Biocon’s subsidiary Biocon Biologics and partner Mylan have launched insulin glargine injection, under the brand name Semglee, in the US market, said the Bengaluru-based company on Monday. 

Biocon Biologics India and Mylan have launched the product in vial and pre-filled pen presentations in the US, Biocon said. It is approved to help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2 diabetes. Mylan, which is responsible for commercialisation in the US, would offer Semglee at a wholesale cost of $147.98 per package of five 3ml pens and $98.65 per 10ml vial, making

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in